Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema

Batıoğlu, Figen; Özmert, Emin; Parmak, Neslihan; Çelik, Selcen

doi:10.1007/s10792-007-9072-7

Cited by 30 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many authors [6][7][8][9][10] found that intravitreal injection of triamcinolone has a shortterm positive effect on diffuse and persisting DME after laser therapy, but its application leads to local complications like raised intraocular pressure and development of cataract [6,10].…”

Section: Introductionmentioning

confidence: 99%

Optical Coherence Tomography Patterns in Diabetic Macular Edema can Predict the Effectiveness of Intravitreal Bevacizumab Combined with Macular Photocoagulation

Radovanova¹

2014

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose: To compare the effectiveness of intravitreal bevacizumab (IVB) combined with macular photocoagulation (MPC) for the treatment of patients with different optical coherence tomography (OCT) patterns of diabetic macular edema. Methods:In this prospective study were included 72 eyes of 58 patients with nonproliferative diabetic retinopathy (NPDR) and nontractional DME with central macular thickness (CMT) over 300 μm. The eyes were categorized into three groups according to OCT features: 22 eyes with diffuse retinal thickening (DRT), 30 eyes with cystoid macular edema (CME), 20 eyes with serous retinal detachment (SRD). All patients received a single dose (1.25mg/0.05ml) of IVB. MPC was applied one month later (25-30 days). Early Treatment Diabetic Retinopahty Study ( ETDRS) best corrected visual acuity (BCVA) and СМТ were assessed before and after the treatment (in the 1st, 3rd and 6th month).Results: At month 6, mean BCVA changed with +8.27 ± 10.7 ETDRS letters (P=0.074), -0.97 ± 8.2 ETDRS letters (P=0.351) and +1.8 ± 10.1 ETDRS letters (P=0.925), respectively, for DRT, CME and SRD groups. Mean CMT decreased by 80.7 ± 65.7 μm (P=0.003) in DRT group, by 24.5 ± 104.6 μm (P=0.909) in CME group and by 51.7 ± 124.3 μm (P=0.580) in SRD group. The DRT group was associated with superior BCVA improvement and greater reduction in CMT as compared with the CME and SRD groups. Conclusions:Intravitreal injection of bevacizumab combined with MPC is more effective in the DRT pattern than in the CME or SRD patterns of DME. The pattern of DME shown by OCT may predict the effectiveness of combination treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Optical Coherence Tomography Patterns in Diabetic Macular Edema can Predict the Effectiveness of Intravitreal Bevacizumab Combined with Macular Photocoagulation

Radovanova¹

2014

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Robert Machemer and colleagues in particular thought about intravitreal triamcinolone acetonide (IVTA) as a therapy of proliferative vitreoretinopathy [1,3,4,9,13,14,15,16]. As a consequence of Machemer’s suggestion, IVTA has been used for the treatment of other intraocular proliferative, edematous and neovascular diseases such as proliferative diabetic retinopathy [17,18], diffuse diabetic macular edema (DME) and diabetic retinopathy in general [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79], branch retinal vein occlusion (BRVO) [80,81,82,83,84,85,86,87,88,89,90,91,92], central retinal vein occlusion (CRVO) […”

Section: Introductionmentioning

confidence: 99%

Intravitreal Triamcinolone

Tao

Jonas

2010

Ophthalmologica

View full text Add to dashboard Cite

Background: To provide an update on the intravitreal use of triamcinolone acetonide. Methods: Review of literature regarding triamcinolone-related research. Results: After the introduction of bevacizumab and ranibizumab into clinical practice, intravitreal triamcinolone has lost its leading position as the drug most often injected intravitreally. Due to its properties as a long-acting steroid, triamcinolone has still been used for various conditions such as diffuse diabetic macular edema, retinal vein occlusions, pseudophakic cystoid macular edema, chronic prephthisical ocular hypotony and uveitis, and in combination with bevacizumab or ranibizumab. The complications of intravitreal triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected, cataract and postoperative infectious or noninfectious endophthalmitis. Conclusions: Due to its widespread biological effects as a steroid and due to a relatively large therapeutic window, intravitreal triamcinolone has remained in clinical use for a variety of intraocular disorders, and it may be a promising candidate for intravitreal medical combination therapies.

show abstract

“…A média de tratamentos foi de 2,6 no grupo tratado (n:34) e de 1,8 no grupo placebo (n:35). Outro estudo não controlado com dois anos de acompanhamento utilizando a dose de 4 mg intravítrea (40) , observou uma diferença significante da espessura macular central (OCT) entre o pré-tratamento e o 3º dia, 1º, 3º, 6º, 9º, 12º, 18º e 24º meses pós-aplicação (p<0,001). Porém, a acuidade visual média (logMAR) obteve melhora significante somente no 1º e 3º meses de acompanhamento (p<0,05), as visitas entre o 6º, 24º meses não obtiveram melhora significante da acuidade visual média (p>0,05).…”

Section: Discussionunclassified

Análise da espessura macular pela tomografia de coerência óptica no edema macular refratário de origem diabética após aplicação de triancinolona intravítrea

Pinheiro¹,

Serracarbassa²,

Maia³

et al. 2007

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema

Cited by 30 publications

References 23 publications

Optical Coherence Tomography Patterns in Diabetic Macular Edema can Predict the Effectiveness of Intravitreal Bevacizumab Combined with Macular Photocoagulation

Optical Coherence Tomography Patterns in Diabetic Macular Edema can Predict the Effectiveness of Intravitreal Bevacizumab Combined with Macular Photocoagulation

Intravitreal Triamcinolone

Análise da espessura macular pela tomografia de coerência óptica no edema macular refratário de origem diabética após aplicação de triancinolona intravítrea

Contact Info

Product

Resources

About